Table 1.
Demographic and clinical characteristics of healthy individuals, PsA and RA patients.
| Characteristics* | HI(n=10) | PsA(n=30) | RA(n=10) | P value |
|---|---|---|---|---|
| Female (%) | 7 (70%) | 22 (73%) | 8 (80%) | |
| Age, years | 41.7 (13) | 51.1 (10) | 54.2 (10) | 0.047 |
| Duration of arthritis, years | - | 6.2 (5.8) | 4 (3.5) | 0.58 |
| Duration of psoriasis, years | – | 20.3 (12.1) | ||
| Disease activity, indices | - | DAPSA 46 (15.3) |
DAS28 5.8 (0.4) |
|
| Enthesitis, n (%) | – | 11 (36%) | – | |
| Dactylitis, n (%) | - | 3 (10%) | - | |
| ESR, mm/hr | – | 23.1 (18.5) | 33.6 (13.4) | 0.2 |
| Current treatment, n | ||||
| Naïve | - | 11 | 0 | |
| DMARDs (methotrexate, leflunomide, apremilast) | 5 | 3 | ||
| Biologic (TNFi, secukinumab, ustekinumab) | 14 | 4 | ||
| Immuno-suppressants (rituximab) | 2 | |||
*All values are presented as ‘mean (SD)’ unless otherwise stated. All variables had <20% missing data. HI, Healthy Individuals; PsA, Psoriatic Arthritis; RA, Rheumatoid Arthritis; DAPSA, Disease Activity Score for Psoriatic Arthritis; DAS28, Disease Activity Score in 28 joints; ESR, Erythrocyte Sedimentation Rate; DMARD, Disease Modifying Anti-rheumatic Drug; TNFi, Tumor Necrosis Factor inhibitors.